Great Point Partners LLC insider trades: Adamas Pharmaceuticals (ADMS) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Great Point Partners LLC reports to the SEC
and 9 more companies
Open-market buys and sales
72 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 21, 2017 | ADMS | ↓ Sell | 380,000 | $17.08 | $6.5M | Investment Mgr. | Jun 21, 2017 (0d) |
| Dec 17, 2014 | CNXR | ↓ Sell | 395,886 | $8.00 | $3.2M | By GPP-Connecture LLC | Dec 17, 2014 (0d) |
| Feb 10, 2011 | INFU | ↓ Sell | 2,070,000 | $2.26 | $4.7M | By Biomedical Offshore Value Fund, Ltd. | Feb 10, 2011 (0d) |
| Feb 10, 2011 | INFU | ↓ Sell | 1,984,542 | $2.26 | $4.5M | By Biomedical Value Fund, L.P. | Feb 10, 2011 (0d) |
| Feb 10, 2011 | INFU | ↓ Sell | 445,458 | $2.26 | $1.0M | By Biomedical Institutional Value Fund, | Feb 10, 2011 (0d) |
| Jan 14, 2010 | BIOD | ↓ Sell10b5-1 | 83,245 | $5.07 | $422K | Direct | Jan 15, 2010 (1d) |
| Jan 12, 2010 | BIOD | ↓ Sell10b5-1 | 69,210 | $5.03 | $348K | Direct | Jan 13, 2010 (1d) |
| Dec 31, 2009 | BIOD | ↓ Sell10b5-1 | 78,890 | $5.06 | $399K | Direct | Jan 5, 2010 (5d) |
| Oct 21, 2009 | BIOD | ↓ Sell10b5-1 | 1,300 | $5.00 | $7K | Direct | Oct 23, 2009 (2d) |
| Oct 19, 2009 | BIOD | ↓ Sell10b5-1 | 3,267 | $5.02 | $16K | Direct | Oct 21, 2009 (2d) |
| Oct 16, 2009 | BIOD | ↓ Sell10b5-1 | 14,600 | $5.06 | $74K | Direct | Oct 19, 2009 (3d) |
| Oct 14, 2009 | BIOD | ↓ Sell10b5-1 | 16,900 | $5.22 | $88K | Direct | Oct 15, 2009 (1d) |
| Oct 12, 2009 | BIOD | ↓ Sell10b5-1 | 13,463 | $5.19 | $70K | Direct | Oct 13, 2009 (1d) |
| Oct 8, 2009 | BIOD | ↓ Sell10b5-1 | 26,013 | $5.18 | $135K | Direct | Oct 9, 2009 (1d) |
| Oct 6, 2009 | BIOD | ↓ Sell10b5-1 | 15,919 | $5.23 | $83K | Direct | Oct 7, 2009 (1d) |
| Sep 23, 2009 | BIOD | ↓ Sell10b5-1 | 9,795 | $5.20 | $51K | Direct | Sep 24, 2009 (1d) |
| Sep 21, 2009 | BIOD | ↓ Sell10b5-1 | 14,135 | $5.22 | $74K | Direct | Sep 22, 2009 (1d) |
| Sep 17, 2009 | BIOD | ↓ Sell10b5-1 | 10,667 | $5.20 | $55K | Direct | Sep 18, 2009 (1d) |
| Sep 15, 2009 | BIOD | ↓ Sell10b5-1 | 26,900 | $5.26 | $142K | Direct | Sep 16, 2009 (1d) |
| Sep 11, 2009 | BIOD | ↓ Sell10b5-1 | 8,600 | $5.19 | $45K | Direct | Sep 14, 2009 (3d) |
| Sep 9, 2009 | BIOD | ↓ Sell10b5-1 | 4,503 | $5.13 | $23K | Direct | Sep 10, 2009 (1d) |
| Sep 4, 2009 | BIOD | ↓ Sell10b5-1 | 6,300 | $5.03 | $32K | Direct | Sep 8, 2009 (4d) |
| Sep 1, 2009 | BIOD | ↓ Sell10b5-1 | 2,023 | $5.05 | $10K | Direct | Sep 3, 2009 (2d) |
| Aug 31, 2009 | BIOD | ↓ Sell10b5-1 | 3,900 | $5.04 | $20K | Direct | Sep 1, 2009 (1d) |
| Aug 27, 2009 | BIODEL | ↓ Sell10b5-1 | 5,900 | $5.14 | $30K | Direct | Aug 28, 2009 (1d) |
| Aug 25, 2009 | BIOD | ↓ Sell10b5-1 | 14,600 | $5.22 | $76K | Direct | Aug 26, 2009 (1d) |
| Aug 21, 2009 | BIOD | ↓ Sell10b5-1 | 8,100 | $5.03 | $41K | Direct | Aug 24, 2009 (3d) |
| Aug 19, 2009 | BIOD | ↓ Sell10b5-1 | 6,500 | $5.00 | $33K | Direct | Aug 20, 2009 (1d) |
| Dec 8, 2008 | MEMY | ↓ Sell | 22,797 | $0.59 | $13K | By Biomedical Value Fund, L.P. | Dec 11, 2008 (3d) |
| Dec 8, 2008 | MEMY | ↓ Sell | 19,418 | $0.59 | $11K | By Biomedical Offshore Value Fund, Ltd. | Dec 11, 2008 (3d) |
| Dec 5, 2008 | MEMY | ↓ Sell | 527,702 | $0.59 | $311K | By Biomedical Value Fund, L.P. | Dec 11, 2008 (6d) |
| Dec 5, 2008 | MEMY | ↓ Sell | 449,523 | $0.59 | $265K | By Biomedical Offshore Value Fund, Ltd. | Dec 11, 2008 (6d) |
| Jul 8, 2008 | MEDE | ↓ Sell | 241,464 | $6.63 | $1.6M | By Biomedical Offshore Value Fund, Ltd. | Jul 9, 2008 (1d) |
| Jul 8, 2008 | MEDE | ↓ Sell | 135,723 | $6.58 | $893K | By Biomedical Value Fund, L.P. | Jul 9, 2008 (1d) |
| Jul 1, 2008 | MEDE | ↑ Buy | 161,755 | $6.65 | $1.1M | By Biomedical Value Fund, L.P. | Jul 9, 2008 (8d) |
| Nov 5, 2007 | MEMY | ↓ Sell | 205,092 | $1.02 | $210K | By Biomedical Value Fund, L.P. | Nov 6, 2007 (1d) |
| Nov 5, 2007 | MEMY | ↓ Sell | 174,708 | $1.02 | $179K | By Biomedical Offshore Value Fund, Ltd. | Nov 6, 2007 (1d) |
| Oct 23, 2007 | MEMY | ↓ Sell | 332,640 | $0.94 | $311K | By Biomedical Value Fund, L.P. | Oct 24, 2007 (1d) |
| Oct 22, 2007 | MEMY | ↓ Sell | 283,360 | $0.94 | $265K | By Biomedical Offshore Value Fund, Ltd. | Oct 24, 2007 (2d) |
| Oct 17, 2007 | MEMY | ↓ Sell | 463,860 | $0.95 | $439K | By Biomedical Value Fund, L.P. | Oct 22, 2007 (5d) |
| Oct 17, 2007 | MEMY | ↓ Sell | 395,140 | $0.95 | $374K | By Biomedical Offshore Value Fund, Ltd. | Oct 22, 2007 (5d) |
| Oct 16, 2007 | MEMY | ↓ Sell | 1,115,967 | $1.07 | $1.2M | By Biomedical Value Fund, L.P. | Oct 17, 2007 (1d) |
| Oct 16, 2007 | MEMY | ↓ Sell | 950,578 | $1.01 | $958K | By Biomedical Offshore Value Fund, Ltd. | Oct 17, 2007 (1d) |
| Jan 16, 2007 | ISPH | ↓ Sell | 270,000 | $7.31 | $2.0M | By Biomedical Value Fund, L.P. | Jan 18, 2007 (2d) |
| Jan 16, 2007 | ISPH | ↓ Sell | 230,000 | $7.31 | $1.7M | By Biomedical Offshore Value Fund, Ltd. | Jan 18, 2007 (2d) |
| Jun 28, 2006 | ISPH | ↑ Buy | 169,000 | $4.03 | $681K | By Biomedical Offshore Value Fund, Ltd. | Jun 30, 2006 (2d) |
| Jun 28, 2006 | ISPH | ↑ Buy | 156,000 | $4.03 | $629K | By Biomedical Value Fund, L.P. | Jun 30, 2006 (2d) |
| Mar 22, 2006 | AVM | ↓ Sell | 214,240 | $30.70 | $6.6M | By Biomedical Offshore Value Fund, Ltd. | Mar 23, 2006 (1d) |
| Mar 22, 2006 | AVM | ↓ Sell | 197,760 | $30.70 | $6.1M | By Biomedical Value Fund, L.P. | Mar 23, 2006 (1d) |
| Mar 20, 2006 | AVM | ↓ Sell | 53,560 | $31.58 | $1.7M | By Biomedical Offshore Value Fund, Ltd | Mar 21, 2006 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Great Point Partners LLC's insider trades
Great Point Partners LLC is a 10% owner of Adamas Pharmaceuticals (ADMS). Since Jul 12, 2005, it has reported 3 open-market purchases worth $2.4M and 69 sales worth $91.7M on SEC Form 4. There have been no open-market trades in the last 12 months.
23 sales (2% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Its filings also include grants and awards (8 filings), shares returned to the company (3 filings), conversions (3 filings), other transactions (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ADMS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.